Skip to content
PodParley
Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further episode artwork

EPISODE · Dec 15, 2025 · 36 MIN

Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further

from Biotech CEO Sisterhood · host BiotechTV

Interviewed by Sisterhood editorial board member Daphne Zohar, Kate Haviland talks about the numerous programs that Blueprint created, the rationale behind key go/no-go and partnering decisions, and how she feels about the biotech sector today.

Episode metadata supplied by the publisher feed · Published Dec 15, 2025

Embed this episode

Ready to play

Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further

0:00 36:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Biotech CEO Sisterhood?

This episode is 36 minutes long.

When was this Biotech CEO Sisterhood episode published?

This episode was published on December 15, 2025.

Can I download this Biotech CEO Sisterhood episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!